CD44, a therapeutic target for metastasising tumours.
Orian-Rousseau
Véronique
V
Karlsruhe Institute of Technology, Institute for Toxicology and Genetics, Hermann von Helmholtzplatz 1, 76344 Eggenstein-Leopoldshafen, Germany. veronique.orian-rousseau@kit.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002633:Chemotaxis / Q000502:physiology; D006801:Humans; D018960:Hyaluronan Receptors / Q000502:physiology*; D006820:Hyaluronic Acid / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000503:physiopathology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D014411:Neoplastic Stem Cells / Q000502:physiology; D053495:Osteopontin / Q000502:physiology; D020033:Protein Isoforms / Q000502:physiology; D051381:Rats
D000970:Antineoplastic Agents; D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins; D020033:Protein Isoforms; D053495:Osteopontin; D006820:Hyaluronic Acid